The writer is a science commentator
What a difference a month makes. In February, scientists reported that an experimental vaccine showed promise in a small group of patients with pancreatic cancer, a disease that is often diagnosed late and carries a notoriously poor prognosis.
The vaccine — using messenger RNA (mRNA) technology similar to that found in some Covid vaccines — activated tumour-targeting immune cells that persisted for nearly four years after surgery in some patients. Not all 16 recipients produced an immune response but those who did were less likely to see their cancer recur. These early findings, from the Memorial Sloan Kettering Cancer Center in New York, have already spurred a follow-up study.
您已閱讀16%（720字），剩餘84%（3869字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。